Prediction: This Undervalued Stock Could Compete With Novo Nordisk by 2029

Novo Nordisk (NYSE: NVO), a Denmark-based drugmaker, is currently a leader in the rapidly growing weight loss market. The company's Wegovy has practically become a household name, and it has plenty more pipeline candidates in the works.However, this area is attracting many more challengers looking to capitalize on its fast expansion. One of them is Viking Therapeutics (NASDAQ: VKTX), a mid-cap biotech. This smaller drugmaker has had a challenging year. But at current levels, it could have plenty of upside as the company works toward launching its first weight management medicine in the next few years.Image source: Getty Images.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool